Artwork

Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

02_10 BRCA Positive Breast Cancer in the Clinic

21:39
 
Distribuie
 

Manage episode 357983519 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

1. BRCA 1/2 genes and relation to malignancy
2. Family history taking and identifying patients for genetic testing
3. Risk reduction strategies for breast and ovarian cancer
4. Systemic therapy considerations in BRCA positive breast cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Litton JK et al. NEJM. 2018;379(8):753-763. doi:10.1056/NEJMOA1802905/

2. Geyer CE et al. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159

3. Robson M et al. NEJM. 2017;377(6):523-533. doi:10.1056/NEJMOA1706450/

4. Tutt ANJ et al. NEJM. 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215/

5. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes

6. Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women

7. Chiarelli AM et al. JCO. 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.8331

8. Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episoade

Artwork
iconDistribuie
 
Manage episode 357983519 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

1. BRCA 1/2 genes and relation to malignancy
2. Family history taking and identifying patients for genetic testing
3. Risk reduction strategies for breast and ovarian cancer
4. Systemic therapy considerations in BRCA positive breast cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Litton JK et al. NEJM. 2018;379(8):753-763. doi:10.1056/NEJMOA1802905/

2. Geyer CE et al. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159

3. Robson M et al. NEJM. 2017;377(6):523-533. doi:10.1056/NEJMOA1706450/

4. Tutt ANJ et al. NEJM. 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215/

5. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes

6. Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women

7. Chiarelli AM et al. JCO. 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.8331

8. Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episoade

Toate episoadele

×
 
1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Finn RS, et al. Oncologist . 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183 2. Pfister D et al. Nature 2021 592:7854 . 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0 3. Zhu AX et al. Lancet Oncol . 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9 4. Abou-Alfa GK, et al. NEJM Evidence . 2022;1(8). doi:10.1056/EVIDOA2100070 5. Kudo M, et al. Lancet . 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 7. Llovet JM, et al. NEJM . 2008;359(4):378-390. doi:10.1056/NEJMOA0708857 8. Reig M, et al.. J Hepatol . 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018 9. Cheng AL et al. J Hepatol . 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 10. Finn RS et al. NEJM . 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/ 11. Rose S, et al. Lancet . 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Pico JL et al. Ann Oncol . 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228 2. Adra N, et al. J Clin Oncol . 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395 3. Nichols CR et al. J Clin Oncol . 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287 4. de Wit R et al.. JCO . 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837 5. Culine S, et al. Ann Oncol . 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062 6. Lorch A, et al. Journal of Clinical Oncology . 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086 7. Fung C, et al.. J Natl Compr Canc Netw . 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Hiester A et al. Eur J Cancer . 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022 2. Calaway AC et al. Eur Urol . 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031 3. Oliver RTD et al. J Clin Oncol . 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655 4. Oliver RTD et al. Lancet . 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X 5. Joffe JK et al. J CO . 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/ 6. Bhatia S et al.. J NCCN . 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040 7. Stephenson A et al. J Urol . 2019;202(2):272-281. doi:10.1097/JU.0000000000000318 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545 Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675 Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044 Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714 Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501 Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023 Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126 Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716 Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090 Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Risk Factors and Presentation 2. Staging and Paraneoplastic syndromes 3. Localized Therapy Options and Considerations 4. Evidence and Limitations for Adjuvant Systemic Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology . 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG 2. Ravaud A et al. NEJM . 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/ 3. Pal SK et al. Lancet . 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0 4. Motzer RJ et al. Lancet . 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0 5. Correa AF et al. Eur Urol . 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025 6. Choueiri TK et al. NEJM . 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/ 7. Choueiri TK et al. NEJM . 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Powles T et al. NEJM . 2024;390(10):875-888. doi:10.1056/NEJMOA2312117/ 2. Powles T et al. NEJM . 2020;383(13):1218-1230. doi:10.1056/NEJMOA2002788/ 3. Galsky MD et al. Lancet . 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0 4. Powles T et al. Lancet Oncol . 2021;22(7):931-945. doi:10.1016/S1470-2045(21)00152-2 5. van der Heijden MS et al. NEJM . 2023;389(19):1778-1789. doi:10.1056/NEJMOA2309863/ 6. Von der Maase H et al. JCO . 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068/ 7. von der Maase H et al. JCO . 2023;41(23):3881-3890. doi:10.1200/JCO.22.02763 8. Vuky J et al. . JCO . 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Etymology, presentation, and work-up of bladder/urothelial cancer 2. Role of perioperative systemic therapy 3. Tri-modality therapy (bladder sparing approach) 4. Considerations for upper tract urothelial cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Bellmunt J et al. Lancet Oncol . 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8 2. Birtle AJ et al. JCO . Published online February 13, 2024. doi:10.1200/JCO.23.01659 3. Birtle A et al. Lancet . 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3 4. Bajorin DF et al. NEJM . 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/ 5. James ND et al. NEJM . 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/ 6. Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507 7. Pfister C et al. Eur Urol . 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024 8. Grossman HB et al. NEJM . 2003;349(9):859-866. doi:10.1056/NEJMOA022148/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Clinical presentation and work-up 2. Intestinal and pancreatobiliary subtypes 3. Role of perioperative therapy 4. Considerations for metastatic disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Neoptolemos JP et al. JAMA . 2010;304(10):1073-1081. doi:10.1001/JAMA.2010.1275 2. Smeenk HG et al.. Ann Surg . 2007;246(5):734-740. doi:10.1097/SLA.0B013E318156EEF3 3. Chang DK , et al. J Clin Oncol . 2013;31(10):1348-1356. doi:10.1200/JCO.2012.46.8868 4. Schueneman A et al. Br J Cancer . 2015;113(1):64-68. doi:10.1038/BJC.2015.172 5. Chiorean EG et al. Journal of the National Comprehensive Cancer Network . 2023;21(7):753-782. doi:10.6004/JNCCN.2023.0034 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. On continuation of ADT and ARAT switch 2. Systemic therapy options after progression 3. Improper mandated crossover 4. PARP inhibitors in prostate cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Freedland SJ et al. NEJM . 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/ 2. de Bono J et al. NEJM . 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/ 3. Haslam A, Prasad V. Annals of Oncology . 2018;29(5):1079. doi:10.1093/ANNONC/MDY116 4. Parker C et al. NEJM . 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/ 5. Khalaf DJ et al. Lancet Oncol . 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6 6. Saad F et al.. J Natl Cancer Inst . 2004;96(11):879-882. doi:10.1093/JNCI/DJH141 7. Sartor O et al. NEJM . 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/ 8. de Wit R et al. NEJM . 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. The chemotherapy revolution in prostate cancer 2. Role of ARATs in earlier disease states 3. Triple therapy (chemotherapy, ADT, and ARAT) 4. Considerations for frailer patients with indolent disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Hussain M et al.. J Clin Oncol . 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041 2. Smith MR et al. NEJM . 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/ 3. Fizazi K et al. Lancet . 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1 4. Sweeney CJ et al. Lancet Oncol . 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3 5. Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2 . 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4 6. Gravis G et al. Lancet Oncol . 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0 7. James ND et al. NEJM . 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/ 8. Fizazi K, et al. Lancet Oncol . 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8 9. James ND et al. Lancet . 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5 10. Gravis G et al. Lancet Oncol . 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0 11. Sweeney CJ et al. NEJM . 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\ 12. James ND et al. The Lancet . 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5 13. Fizazi K et al. NEJM . 2017;377(4):352-360. doi:10.1056/NEJMOA1704174 14. Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720 15. Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Physiology, efficacy and toxicities of androgen deprivation 2. Evidence for adjuvant intervention after definitive surgery or radiation 3. Role of abiraterone in high-risk localized prostate cancer 4. Limited evidence to support definitive salvage approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Attard G et al. Lancet . 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5 2. Xie W et al. J Clin Oncol . 2017;35(27):3097-3104. doi:10.1200/JCO.2017.73.9987 3. Bolla M et al.. NEJM . 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/ 4. Kishan AU et al. Lancet Oncol . 2022;23(2):304-316. doi:10.1016/S1470-2045(21)00705-1 5. Bolla M et al. Lancet . 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4 6. Bolla M et al. Lancet Oncol . 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0 7. Bolla M et al. NEJM . 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/ 8. Hanks GE et al. J Clin Oncol . 2003;21(21):3972-3978. doi:10.1200/JCO.2003.11.023 9. Bolla M et al. Lancet . 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4 10. Huggins C, Hodges C V. CA Cancer J Clin . 1972;22(4):293-297. doi:10.3322/CANJCLIN.22.4.232 11. Huggins C et al. Arch Surg . 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004 12. Rosenthal SA et al. J Clin Oncol . 2019;37(14):1159-1168. doi:10.1200/JCO.18.02158 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Background and presentation of prostate Cancer 2. Evidence behind PSA screening and hallmarks of a screening test 3. Staging and risk stratification of Localized Disease 4. Management options and the ProtecT Trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.Schroder F et al. NEJM . 2009; 360 (13):1320-1328. doi: 10.1056/NEJMOA0810084/ 2. Andriole G el al. NEJM . 2009; 360 (13):1310-1319. doi: 10.1056/NEJMOA0810696/ 3. Lane J et al. Lancet . 2014; 15 (10):1109-1118. doi: 10.1016/S1470-2045(14)70361-4 4. Hamdy F et al. NEJM . 2016; 375 (15):1415-1424. doi: 10.1056/NEJMOA1606220 5. Hamdy F et al. NEJM. 2023; 388 (17):1547-1558. doi: 10.1056/NEJMOA2214122/ 6. Ilic D et al. BMJ. 2018; 362 :k3519. doi:10.1136/BMJ.K3519 7.Maurer T et al. Nat Rev Urol. 2016; 13 (4):226-235. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Role for definitive chemotherapy and radiation 2. Controversy on induction chemotherapy 3. Considerations for nasopharyngeal cancer 4. Approach to metastatic HNSCC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Burtness B et al. J Clin Oncol . 2022;40(21):2321-2332. doi:10.1200/JCO.21.02198 2. Burtness B et al. Lancet . 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7 3. Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656 4. Gibson MK et al. JCO . 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057 5. Zhang L et al. Lancet . 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-5 6. Zhang Y et al. NEJM . 2019;381(12):1124-1135. doi:10.1056/NEJMOA1905287 7. Gau M et al. Oral Oncol . 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.015 8. GT W, et al. NEJM . 1991;324(24):1685-1690. doi:10.1056/NEJM199106133242402 9. Lacas B et al. Radiother Oncol . 2021;156:281. doi:10.1016/J.RADONC.2021.01.013 10. Bourhis et al. JCO . 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.5505 11. Gyawali B et al. Cancer Treat Rev . 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.002 12. Forastiere AA et al. J Clin Oncol . 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245 13. Posner MR et al. NEJM . 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956/ Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Anatomy, diagnostic work-up and staging 2. Field cancerization 3. Indications for adjuvant concurrent chemoradiation 4. Evidence to support weekly cisplatin with concurrent radiation Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Bernier J et al. Head Neck . 2005;27(10):843-850. doi:10.1002/HED.20279 2. Zevallos JP et al. Head Neck . 2021;43(1):108. doi:10.1002/HED.26465 3. Young A, Okuyemi OT. StatPearls . Published online January 12, 2023. Accessed October 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK563022/ 4. Kiyota N et al. J Clin Oncol . 2022;40(18):1980-1990. doi:10.1200/JCO.21.01293 5. Sharma P et al. J Clin Oncol . 2022;40(16). doi: 10.1200/JCO.2022.40.16_suppl.6004 6. Cooper JS et al. NEJM . 2004;350(19):1937-1944. doi:10.1056/NEJMOA032646 7. Bernier J et al. NEJM. 2004;350(19):1945-1952. doi:10.1056/NEJMOA032641 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
1. Presentation, and considerations for regional mesothelioma 2. Systemic therapy options for advanced mesothelioma 3. Corticosteroids for pemetrexed, paclitaxel and docetaxel 4. A quick review on considerations for LCNEC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Peters S et al. Ann Oncol . 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074 2. Baas P et al. Lancet . 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8 3. Vogelzang NJ et al. J Clin Oncol . 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136 4. Zalcman G, et al. Lancet . 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-6 5. Santoro A, et al. J Thorac Oncol . 2008;3(7):756-763. doi:10.1097/JTO.0B013E31817C73D6 6. Lindsay CR et al. Br J Cancer 2021;125(9):1210-1216. doi:10.1038/s41416-021-01407-9 Disclosures Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology…
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință

Listen to this show while you explore
Play